Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma.

Watt SA, Pourreyron C, Purdie K, Hogan C, Cole CL, Foster N, Pratt N, Bourdon JC, Appleyard V, Murray K, Thompson AM, Mao X, Mein C, Bruckner-Tuderman L, Evans A, McGrath JA, Proby CM, Foerster J, Leigh IM, South AP.

Oncogene. 2011 Nov 17;30(46):4666-77. doi: 10.1038/onc.2011.180. Epub 2011 May 23.

2.

Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.

Nihal M, Stutz N, Schmit T, Ahmad N, Wood GS.

Cell Cycle. 2011 Apr 15;10(8):1303-11. Epub 2011 Apr 15.

PMID:
21436619
4.

Polo-like kinase 1 (Plk1) in non-melanoma skin cancers.

Schmit TL, Zhong W, Nihal M, Ahmad N.

Cell Cycle. 2009 Sep 1;8(17):2697-702. Epub 2009 Sep 2.

5.

Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.

Gerster K, Shi W, Ng B, Yue S, Ito E, Waldron J, Gilbert R, Liu FF.

Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):253-60. doi: 10.1016/j.ijrobp.2009.11.027.

PMID:
20394857
6.

Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.

Al-Rohil RN, Tarasen AJ, Carlson JA, Wang K, Johnson A, Yelensky R, Lipson D, Elvin JA, Vergilio JA, Ali SM, Suh J, Miller VA, Stephens PJ, Ganesan P, Janku F, Karp DD, Subbiah V, Mihm MC, Ross JS.

Cancer. 2016 Jan 15;122(2):249-57. doi: 10.1002/cncr.29738. Epub 2015 Oct 19.

7.

Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells.

Schmit TL, Zhong W, Setaluri V, Spiegelman VS, Ahmad N.

J Invest Dermatol. 2009 Dec;129(12):2843-53. doi: 10.1038/jid.2009.172. Epub 2009 Jun 25.

8.

Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.

Ding Y, Huang D, Zhang Z, Smith J, Petillo D, Looyenga BD, Feenstra K, Mackeigan JP, Furge KA, Teh BT.

Cancer Res. 2011 Aug 1;71(15):5225-34. doi: 10.1158/0008-5472.CAN-11-0076. Epub 2011 Jun 3.

9.

MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1.

Liu J, Lu KH, Liu ZL, Sun M, De W, Wang ZX.

BMC Cancer. 2012 Nov 14;12:519. doi: 10.1186/1471-2407-12-519.

10.

Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.

Xu WJ, Zhang S, Yang Y, Zhang N, Wang W, Liu SY, Tian HW, Dai L, Xie Q, Zhao X, Wei YQ, Deng HX.

Cancer Biother Radiopharm. 2011 Aug;26(4):427-36. doi: 10.1089/cbr.2010.0922. Epub 2011 Jul 28.

PMID:
21797676
11.

Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.

Mok WC, Wasser S, Tan T, Lim SG.

World J Gastroenterol. 2012 Jul 21;18(27):3527-36. doi: 10.3748/wjg.v18.i27.3527.

12.

Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells.

Han DP, Zhu QL, Cui JT, Wang PX, Qu S, Cao QF, Zong YP, Feng B, Zheng MH, Lu AG.

Med Sci Monit. 2012 Jun;18(6):BR237-46.

13.

Polo-like kinase 1 is a potential therapeutic target in human melanoma.

Jalili A, Moser A, Pashenkov M, Wagner C, Pathria G, Borgdorff V, Gschaider M, Stingl G, Ramaswamy S, Wagner SN.

J Invest Dermatol. 2011 Sep;131(9):1886-95. doi: 10.1038/jid.2011.136. Epub 2011 Jun 9.

14.

Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma.

Riihilä PM, Nissinen LM, Ala-aho R, Kallajoki M, Grénman R, Meri S, Peltonen S, Peltonen J, Kähäri VM.

J Invest Dermatol. 2014 Feb;134(2):498-506. doi: 10.1038/jid.2013.346. Epub 2013 Aug 12.

15.

Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.

Sero V, Tavanti E, Vella S, Hattinger CM, Fanelli M, Michelacci F, Versteeg R, Valsasina B, Gudeman B, Picci P, Serra M.

Invest New Drugs. 2014 Dec;32(6):1167-80. doi: 10.1007/s10637-014-0158-6. Epub 2014 Sep 7.

PMID:
25193492
16.

Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.

Zhang R, Shi H, Ren F, Liu H, Zhang M, Deng Y, Li X.

Oncol Rep. 2015 Mar;33(3):1235-42. doi: 10.3892/or.2015.3723. Epub 2015 Jan 15.

PMID:
25592872
17.

Intravenous liposomal delivery of the short hairpin RNAs against Plk1 controls the growth of established human hepatocellular carcinoma.

Deng H, Jiang Q, Yang Y, Zhang S, Ma Y, Xie G, Chen X, Qian Z, Wen Y, Li J, Yang J, Chen L, Zhao X, Wei Y.

Cancer Biol Ther. 2011 Feb 15;11(4):401-9. Epub 2011 Feb 15.

PMID:
21150280
18.

An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.

Linton A, Cheng YY, Griggs K, Kirschner MB, Gattani S, Srikaran S, Chuan-Hao Kao S, McCaughan BC, Klebe S, van Zandwijk N, Reid G.

Br J Cancer. 2014 Jan 21;110(2):510-9. doi: 10.1038/bjc.2013.731. Epub 2013 Dec 10.

19.

The antitumor effect of PLK1 and HSF1 double knockdown on human oral carcinoma cells.

Kim SA, Kwon SM, Yoon JH, Ahn SG.

Int J Oncol. 2010 Apr;36(4):867-72.

PMID:
20198330
20.

Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.

Hu K, Lee C, Qiu D, Fotovati A, Davies A, Abu-Ali S, Wai D, Lawlor ER, Triche TJ, Pallen CJ, Dunn SE.

Mol Cancer Ther. 2009 Nov;8(11):3024-35. doi: 10.1158/1535-7163.MCT-09-0365. Epub 2009 Nov 3.

Supplemental Content

Support Center